Quantcast
Last updated on April 17, 2014 at 15:50 EDT

Latest Imprimis Pharmaceuticals Inc. Stories

2014-03-25 08:28:42

--Company presentation will be webcast/available at www.imprimispharma.com-- SAN DIEGO, March 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13(th) Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET....

2014-03-04 08:30:54

Company presentation will be webcast/available at www.imprimispharma.com SAN DIEGO, March 4, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March. On Monday, March 10, 2014, Mr. Baum is...

2014-02-25 08:30:30

--First-time cataract formulation clinical data and clinical experience will be presented at a U.S. ophthalmic meeting -- SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that James Lewis, MD (http://cataractphiladelphia.com), will present "Dropless Cataract Surgery" during the New Technologies...

2014-02-19 08:29:46

- House to lead company's distribution strategy and pharmacy operations efforts to make and distribute Imprimis' patent-pending formulations - SAN DIEGO, Feb. 19, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this...

2014-02-11 08:30:29

-- Transaction marks important milestone as company approaches commercial launch targeting ophthalmologists -- SAN DIEGO, Feb. 11, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that it has come to an agreement to acquire Pharmacy Creations LLC (www.pharmacycreations.com), a premier, state-of-the-art...

2014-01-28 08:29:07

-Company Continues Go Dropless(TM) Information Campaign Targeted at Ophthalmologists- SAN DIEGO, Jan. 28, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will...

2013-12-09 08:28:19

--Company Continues Path to Advance Personalized Medicine while Striving to Improve Quality and Reduce Americans' Drug Costs-- SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a pharmaceutical company focused on commercial development of novel drug formulations and drug delivery technologies announced their intention today to pursue a compounding pharmacy strategy in 2014 and beyond. The recently passed Drug Quality and Security Act allows...

2013-11-19 08:28:00

SAN DIEGO, Nov. 19, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today voiced support for the U.S. Senate's approval of the Drug Quality and Security Act (H.R. 3204), which clarifies and strengthens the regulatory framework for compounding pharmacies. "Passage of this Bill by the Senate by a voice vote,...

2013-11-12 08:35:15

Saharek to head all commercialization activities for the roll out of two lead proprietary ophthalmic compounded formulations SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced the hiring of John Saharek to serve as Vice-President of Commercialization for Ophthalmology....

2013-11-08 16:24:44

Imprimis to debut its "Go Dropless" campaign to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced that it will be attending the 117(th) Annual...